title: Treatment of diet-resistant polygenic hypercholesterolaemic patients with a new nicotinate derivative; in vivo and in vitro low density lipoprotein metabolic studies.
abstract: Six patients (four women and two men) with mild to moderate hypercholesterolemia, but with no clinical evidence of the disease being monogenic familial hypercholesterolaemia and who, over the previous 3 months on a rigidly controlled hypolipidaemic diet therapy, showed no reduction in plasma cholesterol levels, were recruited into a study to assess the metabolic effects of Pirozadil, a new nicotinic acid derivative. After a 3 month treatment period, a significant reduction in plasma cholesterol from 299.8 +/- 31.2 mg/dl (mean +/- SD) to 256.8 +/- 18.1 mg/dl (P less than 0.02) and Low Density Lipoprotein (LDL) cholesterol from 211.7 +/- 44.9 mg/dl to 168.8 +/- 19.0 mg/dl (P less than 0.05) was observed. Although there was a trend toward decreased plasma and Very Low Density Lipoprotein (VLDL) triglyceride, the differences did not reach statistical significant. High Density Lipoprotein (HDL) cholesterol was unchanged. The drug was well tolerated with no side effects noted. To assess the mode of action, autologous125I-labelled LDL was injected and apoprotein B (apo B) kinetic parameters were measured; production rate (PR) and fractional catabolic rate (FCR). An in vitro measurement of the in vivo catabolism (LDL-apo B receptor activity in freshly isolated lymphocytes) was also measured pre- and post-treatment. The pharmacological intervention resulted in a significant decrease of 19.9% in PR from 10.5 +/- 1.81 mg/kg/d to 8.41 +/- 1.13 mg/kg/d (P less than 0.05) while the FCR remained relatively unchanged (0.260 +/- 0.042 vs 0.248 +/- 0.040 pools/d) as did the LDL receptor activity (78.2 +/- 20.9 vs 69.3 +/- 21.4 ng LDL/mg cell protein/hr).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Unitat de Recerca de Lipids, Hospital de Sant Joan, Facultad de Medicina de Reus, Universidad de Barcelona, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Masana
authors.forename: A
authors.initials: A
authors.lastname: Escobar
authors.forename: J
authors.initials: J
authors.lastname: Joven
authors.forename: R
authors.initials: R
authors.lastname: Solá
authors.forename: E
authors.initials: E
authors.lastname: Vilella
authors.forename: T
authors.initials: T
authors.lastname: Bargallo
authors.forename: P R
authors.initials: PR
authors.lastname: Turner
mesh_terms: D001055:Apolipoproteins B / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy*; D007700:Kinetics; D008077:Lipoproteins, LDL / Q000097:blood* / Q000378:metabolism; D008297:Male; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use*; D011973:Receptors, LDL / Q000378:metabolism
chemical_list: D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008077:Lipoproteins, LDL; D011725:Pyridines; D011973:Receptors, LDL; C015453:pirozadil; D002784:Cholesterol